Elizabeth Proos

Ms. Proos joined Daré Bioscience in November 2019, as part of the acquisition of DARE MB Inc., and she currently serves as Vice President of Product Development. In this role Ms. Proos is responsible for technical and strategic product development, implementing best practice product development and program management approaches. She is also responsible for strategy and product development of DARE-LARC1, a user-controlled, long-acting, reversible contraceptive, and leads a cross-functional R&D and product development team and key strategic external partners.

Throughout her career Ms. Proos has developed and advanced novel products for numerous applications and therapeutic areas through clinical development, including bone substitute materials, pulmonary therapies, injectable sustained release products, and implantable drug delivery devices.  During her 12-year tenure at DARE MB Inc., she developed the candidate formulation and managed the clinical program advancing the legacy company to its First-In-Human clinical study with parathyroid hormone, a treatment for osteoporosis. Ms. Proos also has significant preclinical testing experience and has worked closely with clinical and regulatory affairs as a technical expert to advance complex product development, including a role at Becton Dickenson, where she worked in Medical Affairs as a technical liaison between R&D, clinical and business development groups, and conducted clinical studies for development of a novel continuous glucose monitoring product.

Ms. Proos has also held leadership and technical positions at BD, Lantheus Medical Imaging, Epic Therapeutics (a wholly owned subsidiary of Baxter Healthcare), and Etex Corporation. She has more than 23 years of experience in drug delivery science and product development of combination products and medical devices. Ms. Proos graduated from Wellesley College with a degree in Chemistry.